Sirnaomics

History

Year	Detail
2007	Established Sirnaomics’ U.S. headquarters in Gaithersburg, Maryland
2008	Established Sirnaomics’ China headquarters in Suzhou
2009	Sirnaomics Suzhou was certified as the Suzhou Engineering Research Center for nucleic acid drugs by the Suzhou Science and Technology Bureau
2012	Expanded presence in China with new offices in Guangzhou, China. Sirnaomics Guangzhou was selected as the Guangzhou Entrepreneurship Leading Talent Project
2013	Sirnaomics Suzhou and Sirnaomics Guangzhou were selected as the “Significant New Drug Creation” in the 12th Five-Year Plan for National Economic and Social Development in China
2016	Obtained IND clearance from the U.S. FDA for a Phase ?a clinical study of STP705 in hypertrophic scars
2017	Achieved the first IND approval of STP705 for treating hypertrophic scars in China. Sirnaomics Guangzhou partnered with Jiangsu Zhengyuan to develop a variety of atomization drug delivery devices
2018	Received FDA clearance for Phase ? study of STP705 for squamous cell carcinoma nonmelanoma skin cancer
2019	Established Sirnaomics Hong Kong
2020	Launched RNAimmune, a subsidiary of Sirnaomics.
2021	Established a co-development partnership for STP702 with Walvax. Established a manufacturing facility with fill and finish capacity in Guangzhou to produce large-scale products with GMP compliance
2022	Obtained IND clearance from the Taiwan Ministry of Health and Welfare for STP705 in Liver Cancer Treatment.
2023	Signed the Strategic Enterprise Partnership Agreement with OASES. Establishes a Strategic Partnership with EDIRNA Inc.
2024	Sirnaomics received FDA specific guidance for further development of STP705 for treatment of Squamous Cell Carcinoma in Situ. RNAimmune licensed out the RV-1770 human RSV Vaccine to Hualan Biological Vaccine Inc.